Publicidad
Educación continua 01 de julio de 2011

Conceptualizando V: Comportamiento de la glucosa y la 18F-FDG en tumores malignos, con enfoque en el cáncer de mama

Referenciar Imprimir Descargar PDF

Referencias

  1. Cruz Tapias PA, Villegas Gálvez VE, Ramírez Clavijo SR. Fundamento biológico y aplicación clínica de los marcadores tumorales séricos. Rev Cienc Salud 2008;6:85-98.
  2. Dafang W, Sanjiv S, Gambhir S. Positron emission tomography in diagnosis and management of invasive breast cancer: current status and future perspectives. Clin Breast Cancer 2003;4(suppl 1):S55–S63.
  3. Eubank WB, Mankoff DA, Vesselle HJ, Eary JF, Schubert EK, Dunnwald LK et al. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics 2002;22:5–17.
  4. Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 2000;41:661–81.
  5. Miles KA, Williams RE. Warburg revisited: imaging tumor blood flow and metabolism. Cancer Imaging 2008;8:81–6.
  6. Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K et al. FDG uptake and glucose transporter subtype expression in experimental tumor and inflammation models. J Nucl Med 2001;42:1551–5.
  7. Grover-McKay M, Walsh SA, Seftor EA, Thomas PA, Hendrix MJ. Role for glucose transporter 1 protein in human breast cancer. Pathol Oncol Res 1998;4:115–20.
  8. Burgman P, O’Donoghue JA, Humm JL, Clifton C. Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med. 2001;42:170–5.
  9. Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL, Expression of hexokinase II and glut-1 in untreated human breast cancer. Nucl Med Biol 2002;29:443–53.
  10. Brown RS, Wahl RL. Overexpression of glut-1 glucose transporter in human breast cancer: an immunohistochemical study. Cancer 1993;72:2979–85.
  11. Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42:9–16.
  12. Macheda ML, Rogers S, Bets JD. Molecular and cellular regulation of glucose transport (GLUT) proteins in cancer. J Cell Physiol 2005;202:654–62.
  13. Rogers S, Macheda ML, Docherty SE, Carty MD, Henderson MA, Soeller WC et al. Identification of a novel glucose transporter-like protein-glut-12. Am J Physiol Endocrinol Metab 2002;282:E733–E738.
  14. De Manzoni, G. Studyon KI-67 Immunoreactivity as a Prognostic Indicator in Patients with Advanced Gastric Cancer. Universidad de Verona, Italia, 1998.http://www3.oup.co.uk/jjco/Volume_28/Issue_09/html/hyb128_gml.html
  15. Buck A, Schirrmeister H, Kühn T, Shen C, Kalker T, Kotzerke J et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002;29:1317–23.
  16. Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer 2007;14:260–8.
  17. Pardo Mindán J, Panizo A, Martínez L. Valoración del sistema de polímeros de dextrano En Visión (PDE) en la detección inmunohistoquímica. Revista Española Patología 1998;31:9-16.
  18. Leong A. Applied immunohistochemistry for the surgical pathologist. 1st ed. Edward Arnold, Hodder Headline Group, London, 1993.
  19. Bisgaard K. Polymeric conjugates forenhanced signal generation in enzymeimmunoassays. Scand SocforImmunol (XXIVth Annual Meeting, Aarthus), 1993.
  20. Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A et al. Association between [18F]-fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labeling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 1998;25:1429–34.
  21. Smith TA, Sharma RI, Thompson AM, Paulin FE. Tumor 18F-FDG incorporation is enhanced by attenuation of p53 function in breast cancer cells in vitro. J Nucl Med 2006;47:1525–30.
  22. Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A et al. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res reat 2006;98:267–74.
  23. Basu S, Mavi A, Cermik T, Houseni M, Alavi A. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology? Mol Imaging Biol 2008;10:62–6.
  24. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002;43:500–9.
  25. Kumar V, Abbas AK, Fausto N, Aster J. «Ch3-Tissue Renewal, Regeneration and Repair». En Saunders (Elsevier). Robbins & Cotran Pathologic Basis of Disease (8th edition). New York, 2010.
  26. Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS et al. «International Union of Pharmacology. LXIV. Estrogenreceptors». Pharmacol Rev 2006;58:773–81.
  27. Traish AM, Newton AW, Styperek K, Beazley R, Kavanah M. Estrogen receptor functional status in human breastcancer. Siang Mol Pathol 1995;4: 220-8.
  28. Suárez-Calderón D, Díaz-Yamal I. Antagonistas de receptores de progesterona (PRA) y moduladores selectivos de receptores de progesterona (SPRM): aplicaciones en ginecología y obstetricia. Revista Colombiana de Obstetricia y Ginecología 2008;59:31-7.
  29. Morales L, Reigosa A, Caleiras E, Mora R, Marrero N, Payares E et al. Expresión del HER2/neu en pacientes venezolanas con cáncer de mama localmente avanzado. Invest. clín. [online]. mar. 2008, vol.49, no.1 [citado 04 Junio 2010], p.69-78.
  30. Basu S, Wengen C, Tchou J, Mavi A, Cermik T, Czerniecki B et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 2008;112:995–1000.
  31. Mavi A, Cermik TF, Urhan M, Puskulcu H, Basu S, Yu JQ et al. The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med 2007;48:1266–72.
  32. Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (>18>F-FDG PET/CT)in primary breast cancer. Jpn J Clin Oncol 2008;38:250–8.
  33. Quesada-Chanto A. Diagnóstico de Laboratorio. Principales pruebas de bioquímica clínica y hematología. 1° ed. Litografía e Imprenta Lehmann. San José, Costa Rica, 2003.
  34. Grassetto G, Fornasiero A, Otello D, Bonciarelli G, Rossi E, Nashimben O et al. (18)F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: A multicentre study. Eur J Radiol 2010 May 21 (Epub ahead of print).
  35. Champion L, Brain E, Giraudet AL, Le Stanc E, Wartski M, Edeline V et al. Breast cancer recurrence diagnosis suspected on tumor marker rising. Cancer 2011;117:1621-9.
  36. Welcsh PL, King MC. BRCA-1 and BRCA-2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001;10:705-13.